epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Fabhalta
    iptacopan
  • remove Junel Fe 24
    norethindrone/ ethinyl estradiol
  • remove Libtayo (cemiplimab-rwlc)
    cemiplimab
  • remove Nextstellis
    drospirenone/ estetrol
  • remove Tryvio
    aprocitentan

multicheck MultiCheck Results - 4 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Junel Fe 24 (norethindrone/ ethinyl estradiol) + Nextstellis (drospirenone/ estetrol)

Avoid/Use Alternative


ethinyl estradiol (contraceptive) + estetrol (contraceptive)

avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy)

norethindrone (contraceptive) + drospirenone (contraceptive)

avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

Smiley face Smiley face Junel Fe 24 (norethindrone/ ethinyl estradiol) + Tryvio (aprocitentan)

Monitor/Modify Tx


ethinyl estradiol (contraceptive) + aprocitentan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

Smiley face Smiley face Nextstellis (drospirenone/ estetrol) + Tryvio (aprocitentan)

Monitor/Modify Tx


estetrol (contraceptive) + aprocitentan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information